Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. CME/CE

Multidisciplinary Approach to Diagnosing and Managing Indolent Systemic Mastocytosis: The Changing Landscape

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-Test Skip straight to the post-test if you have already participated in this activity.
Media formats available:
0.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Related
Comments
  • Overview

    Patients with indolent systemic mastocytosis frequently report a symptom burden disproportionate to measurable disease burden. Anti-mediator intervention is not always successful in improving the quality of life of these patients. But the treatment landscape is changing. Join Drs. Cem Akin, Daniel DeAngelo, and Matthew Hamilton offer key clinical insights into this changing standard of care for ISM and discuss why allergists, hematologists, and gastroenterologists are at the vanguard of this change.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Cem Akin, MD
    Professor of Internal Medicine
    University of Michigan
    Ann Arbor, MI 

    Dr. Akin has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: Blueprint Medicine, Cogent
    Consulting fees: Blueprint Medicine, Congent, Novartis 

    Daniel J. DeAngelo, MD, PhD
    Professor of Medicine
    Harvard Medical School
    Dana-Farber Cancer Institute
    Boston, MA

    Dr. DeAngelo has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: Abbvie, Novartis, Blueprint, Glycomimetrics
    Consulting fees: Amgen, Autolus, Blueprint, Gilead, Jazz, Novartis, Pfizer, Servier, Takeda

    Matthew J. Hamilton, MD
    Assistant Professor of Medicine
    Brigham and Women's Hospital
    Chestnut Hill MA

    Dr. Hamilton has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting fees: Blueprint Medicine

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Barry Fiedel has nothing to disclose.
    • Rebecca Barraclough has nothing to disclose.
    • Amanda Mulder has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss indolent systemic mastocytosis (ISM) diagnosis, disease, and symptom burden as it relates to treatment of ISM 
    • Evaluate current and emerging approaches for the multidisciplinary management of ISM 
  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, which includes hematologists, allergists/immunologists and gastroenterologists, as well as other healthcare providers involved in managing patients with Indolent Systemic Mastocytosis (ISM).

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LLC. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours.  Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 CEUs of pharmacy contact hours. 

    The Universal Activity Number for this program is JA0006235-0000-24-046-H01-P.  This learning activity is knowledge-based.  Your CE credits will be electronically submitted to the NABP upon successful completion of the activity.  Pharmacists with questions can contact NABP customer service at custserv@napb.net

  • Provider(s)/Educational Partner(s)

    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care. 

  • Commercial Support

    This activity is supported by an independent educational grant from Blueprint Medicines Corporation.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Recommended
Details
Presenters
Related
Comments
  • Overview

    Patients with indolent systemic mastocytosis frequently report a symptom burden disproportionate to measurable disease burden. Anti-mediator intervention is not always successful in improving the quality of life of these patients. But the treatment landscape is changing. Join Drs. Cem Akin, Daniel DeAngelo, and Matthew Hamilton offer key clinical insights into this changing standard of care for ISM and discuss why allergists, hematologists, and gastroenterologists are at the vanguard of this change.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Cem Akin, MD
    Professor of Internal Medicine
    University of Michigan
    Ann Arbor, MI 

    Dr. Akin has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: Blueprint Medicine, Cogent
    Consulting fees: Blueprint Medicine, Congent, Novartis 

    Daniel J. DeAngelo, MD, PhD
    Professor of Medicine
    Harvard Medical School
    Dana-Farber Cancer Institute
    Boston, MA

    Dr. DeAngelo has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: Abbvie, Novartis, Blueprint, Glycomimetrics
    Consulting fees: Amgen, Autolus, Blueprint, Gilead, Jazz, Novartis, Pfizer, Servier, Takeda

    Matthew J. Hamilton, MD
    Assistant Professor of Medicine
    Brigham and Women's Hospital
    Chestnut Hill MA

    Dr. Hamilton has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting fees: Blueprint Medicine

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Barry Fiedel has nothing to disclose.
    • Rebecca Barraclough has nothing to disclose.
    • Amanda Mulder has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss indolent systemic mastocytosis (ISM) diagnosis, disease, and symptom burden as it relates to treatment of ISM 
    • Evaluate current and emerging approaches for the multidisciplinary management of ISM 
  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, which includes hematologists, allergists/immunologists and gastroenterologists, as well as other healthcare providers involved in managing patients with Indolent Systemic Mastocytosis (ISM).

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LLC. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours.  Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 CEUs of pharmacy contact hours. 

    The Universal Activity Number for this program is JA0006235-0000-24-046-H01-P.  This learning activity is knowledge-based.  Your CE credits will be electronically submitted to the NABP upon successful completion of the activity.  Pharmacists with questions can contact NABP customer service at custserv@napb.net

  • Provider(s)/Educational Partner(s)

    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care. 

  • Commercial Support

    This activity is supported by an independent educational grant from Blueprint Medicines Corporation.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule3 Oct 2024